Benitec Biopharma Inc. (BNTC) 追踪市盈率为负值 -10.7, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 18.9 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -9.33%, 前瞻盈利收益率 5.28%. PEG 0.06 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 54/100 其中 2/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -2.0 | -0.03 | 2.57 | 104.15 | - |
| 2017 | -14.8 | 0.18 | 3.93 | 144.14 | - |
| 2018 | -9.8 | -0.16 | 6.08 | 183.91 | 0.15% |
| 2019 | 13.4 | -0.11 | 2.32 | 3.40 | - |
| 2020 | -3.9 | 0.01 | 3.16 | 333.10 | - |
| 2021 | -5.3 | 0.09 | 3.65 | 1,237.66 | - |
| 2022 | -2.1 | 0.07 | 13.16 | 519.41 | - |
| 2023 | -0.3 | 0.01 | 27.85 | 75.02 | - |
| 2024 | -3.4 | 0.04 | 1.58 | 0.00 | - |
| 2025 | -11.2 | 0.18 | 4.35 | 0.00 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-331.56 | $346.51K | $-18.5M | -5340.1% |
| 2017 | $-63.56 | $450.31K | $-4.37M | -971% |
| 2018 | $-103.61 | $455.45K | $-8.55M | -1877.4% |
| 2019 | $28.45 | $11.32M | $2.87M | 25.3% |
| 2020 | $-69.10 | $97K | $-8.3M | -8557.7% |
| 2021 | $-27.27 | $59K | $-13.78M | -23357.6% |
| 2022 | $-19.31 | $73K | $-18.56M | -25427.4% |
| 2023 | $-14.12 | $75K | $-19.56M | -26082.7% |
| 2024 | $-2.68 | $216K | $-21.75M | -10069.9% |
| 2025 | $-1.05 | $0.00 | $-37.92M | - |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-1.13 | $-1.18 – $-1.04 | $25.43M | $25.43M – $25.43M | 5 |
| 2027 | $-1.11 | $-1.19 – $-1.00 | $36.43M | $36.43M – $36.43M | 5 |
| 2028 | $-0.90 | $-1.12 – $-0.68 | $50.53M | $50.53M – $50.53M | 2 |
| 2029 | $0.70 | $0.70 – $0.70 | $131.05M | $131.05M – $131.05M | 1 |
| 2030 | $2.87 | $2.87 – $2.87 | $286.79M | $286.79M – $286.79M | 1 |
